Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Olutasidenib by Rigel Pharmaceuticals for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Olutasidenib is under clinical development by Rigel Pharmaceuticals and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...
Data Insights
Olutasidenib by Rigel Pharmaceuticals for Myelodysplastic Syndrome: Likelihood of Approval
Olutasidenib is under clinical development by Rigel Pharmaceuticals and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase...